Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 5/20 | 0.45 |
| ▸ | APEX1 | P27695 | 2/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5764587 | 0.84 | NPC1 (0.52) | SMN1; SMN2TDP1NPC1RAB9AHSP90AA1 | |
| SCHEMBL2652982 | 0.78 | HTT (0.46) | SMN1; SMN2TDP1NPC1RAB9AHSP90AA1 | |
| SCHEMBL7015698 | 0.77 | NPC1 (0.56) | SMN1; SMN2TDP1NPC1RAB9AHSP90AA1 | |
| SCHEMBL2651977 | 0.77 | HTT (0.71) | SMN1; SMN2NPC1RAB9AHSP90AA1ALDH1A1 | |
| SCHEMBL18263634 | 0.74 | HTT (0.54) | NPC1RAB9AHSP90AA1ALDH1A1POLB | |
| SCHEMBL901472 | 0.74 | TDP1 (0.72) | SMN1; SMN2TDP1NPC1RAB9AALDH1A1 | |
| SCHEMBL69436 | 0.72 | SELL (0.48) | TDP1NPC1RAB9AALDH1A1POLB | |
| SCHEMBL31154580 | 0.72 | BCL2 (0.47) | ALDH1A1POLBKMT2AMEN1HPGD | |
| SCHEMBL6299900 | 0.72 | THRA (0.49) | NPC1RAB9AESR2ESR1ALOX15 | |
| SCHEMBL5765557 | 0.71 | HTT (0.61) | SMN1; SMN2NPC1RAB9AHSP90AA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1334972-B1 | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH) | PFIZER (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6833372-B2 | A hormone inhibitors of gonadotropin releasing hormone, an antigonadotropins, new drug compound contains a furanyl 2-carboxylic acid -(2,4-dimethoxy-pyrimidin-5-yl)-amide groups | PFIZER, INC. | 2004-12-21 | — | — | US | disclosed |
| US-20040053951-A1 | Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use | PFIZER INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2003068769-A1 | NON-PEPTIDE COMPOUNDS AFFECTING THE ACTION OF GONADOTROPIN-RELEASING HORMONE (GNRH) | PFIZER INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| EP-1334972-A1 | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH) | PFIZER INC. (US) | 2003-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053951-A1 | Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use | GNRHR, LHCGR, FSHR | SMN1; SMN2 4360/4885TDP1 2752/4885NPC1 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.